In a recent phase III trial involving patients with EGFR-mutated oligometastatic NSCLC, the addition of LAT to first-generation EGFR-TKIs (LAT + TKI arm) significantly improved both PFS and OS compared to EGFR-TKIs alone (TKI arm), with median PFS of 20.2 vs. 12.5 months (p < 0.001) and median OS of 25.5 vs. 17.4 months (p < 0.001), respectively [30]. Here, EGFR is linked to non-small cell lung carcinoma.